Literature DB >> 33900081

Gangliosides of Human Glioblastoma Multiforme: A Comprehensive Mapping and Structural Analysis by Ion Mobility Tandem Mass Spectrometry.

Mirela Sarbu1,2, Ligia Petrica3, David E Clemmer4, Željka Vukelić5, Alina D Zamfir1,6.   

Abstract

Glioblastoma multiforme (GBM), a malignant, highly aggressive, grade IV brain tumor, which rapidly infiltrates into the nearby tissue, has drawn a significant amount of attention because of its poor prognosis and the limited treatment options available. In GBM, nearly all tumor cells exhibit aberrant cell-surface glycosylation patterns due to the alteration of their biosynthesis or postsynthesis modification process. Since gangliosides (GGs) are acknowledged as tumor-associated antigens, we have carried out here a comprehensive profiling of native ganglioside mixtures extracted and purified from GBM specimens. For this purpose, high performance ion mobility separation mass spectrometry (IMS MS) was thoroughly optimized to allow the discovery of GBM-specific structures and the assessment of their roles as tumor markers or possible associated antigens. GG separation by IMS according to the charge state, carbohydrate chain length, degree of sialylation, and ceramide composition led to the identification of no less than 160 distinct components, which represents 3-fold the number of structures identified before. The detected GGs and asialo-GGs were found characterized by a high heterogeneity in their ceramide and glycan compositions, encompassing up five Neu5Ac residues. The tumor was found dominated in equal and high proportions by GD3 and GT1 forms, with a particular incidence of C24:1 fatty acids in the ceramide. By the occurrence of only one mobility feature and the diagnostic fragment ions, the IMS tandem MS conducted using collision-induced dissociation (CID) disclosed for the first time the presence of GT1c(d18:1/24:1) newly proposed here as a potential GBM marker.

Entities:  

Keywords:  biomarker; collision-induced dissociation; gangliosides; human glioblastoma multiforme; ion mobility separation/spectrometry mass spectrometry (IMS MS)

Mesh:

Substances:

Year:  2021        PMID: 33900081     DOI: 10.1021/jasms.1c00088

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  6 in total

Review 1.  Mass Spectrometry-Based Techniques to Elucidate the Sugar Code.

Authors:  Márkó Grabarics; Maike Lettow; Carla Kirschbaum; Kim Greis; Christian Manz; Kevin Pagel
Journal:  Chem Rev       Date:  2021-09-07       Impact factor: 72.087

2.  High-Resolution Tandem Mass Spectrometry Identifies a Particular Ganglioside Pattern in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus Patients.

Authors:  Anca Suteanu-Simulescu; Alina Diana Zamfir; Raluca Ica; Mirela Sarbu; Cristian V A Munteanu; Florica Gadalean; Adrian Vlad; Flaviu Bob; Dragos Catalin Jianu; Ligia Petrica
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.927

Review 3.  Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.

Authors:  Angelica Pace; Fabio Scirocchi; Chiara Napoletano; Ilaria Grazia Zizzari; Luca D'Angelo; Antonio Santoro; Marianna Nuti; Hassan Rahimi; Aurelia Rughetti
Journal:  Int J Mol Sci       Date:  2022-06-05       Impact factor: 6.208

4.  Ion Mobility Mass Spectrometry Reveals Rare Sialylated Glycosphingolipid Structures in Human Cerebrospinal Fluid.

Authors:  Mirela Sarbu; Dragana Fabris; Željka Vukelić; David E Clemmer; Alina D Zamfir
Journal:  Molecules       Date:  2022-01-24       Impact factor: 4.411

5.  Mass spectrometry imaging discriminates glioblastoma tumor cell subpopulations and different microvascular formations based on their lipid profiles.

Authors:  Kelly C O'Neill; Evangelos Liapis; Brent T Harris; David S Perlin; Claire L Carter
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

Review 6.  Gangliosides as Biomarkers of Human Brain Diseases: Trends in Discovery and Characterization by High-Performance Mass Spectrometry.

Authors:  Mirela Sarbu; Raluca Ica; Alina D Zamfir
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.